{"gene":"DUSP6","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1998,"finding":"MKP-3/DUSP6 is catalytically activated by direct binding to ERK2; activation requires ERK2 binding to the noncatalytic N-terminus of MKP-3 and is independent of ERK2 kinase activity. The gain-of-function ERK2 mutant D319N, JNK/SAPK, and p38 did not bind MKP-3 or activate it.","method":"In vitro binding and phosphatase activity assays with purified recombinant proteins; mutagenesis (Sevenmaker D319N ERK2)","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified proteins, mutagenesis, replicated across multiple labs","pmids":["9596579"],"is_preprint":false},{"year":1996,"finding":"Pyst1/DUSP6 is a cytoplasmic (not nuclear) dual-specificity phosphatase that selectively dephosphorylates and inactivates ERK/MAP kinase but displays very low activity toward JNK/SAPK and p38 in vitro and in vivo; it forms a physical complex with endogenous MAP kinase in cells.","method":"Subcellular fractionation/immunofluorescence in transfected Cos-1 cells; in vitro phosphatase assay; co-immunoprecipitation; in vivo kinase assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (fractionation, in vitro assay, co-IP, in vivo inhibition), replicated across labs","pmids":["8670865"],"is_preprint":false},{"year":1996,"finding":"MKP-3/DUSP6 is a cytosolic dual-specificity phosphatase that blocks ERK2 phosphorylation and enzymatic activation when expressed in COS-7 cells; subcellular localization in sympathetic neurons is cytosolic with nuclear exclusion.","method":"Transfection in COS-7 cells with kinase assays; in situ hybridization; epitope-tag immunolocalization in neurons","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization experiments plus functional kinase assays, replicated across labs","pmids":["8626780"],"is_preprint":false},{"year":1996,"finding":"MKP-3/DUSP6 selectively inactivates ERK1 but only partially inhibits JNK/SAPK and p38 upon co-expression in COS-7 cells, demonstrating reciprocal selectivity compared to M3/6 phosphatase.","method":"Co-transfection in COS-7 cells; kinase activity assays; dose-response co-transfection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple kinase substrates tested, reciprocal selectivity controls, replicated across labs","pmids":["8910287"],"is_preprint":false},{"year":1999,"finding":"Crystal structure of the Pyst1/DUSP6 catalytic domain at 2.35 Å reveals a protein tyrosine phosphatase fold with a distorted active site; kinetic analysis shows the catalytic domain is sufficient to dephosphorylate ERK2 and is allosterically activated by inactive ERK2; mutation of Asp262 (5.5 Å from active site) abolishes catalysis in the ERK2-dependent high-activity conformation but not the low-activity form, indicating ERK2 induces closure of the Asp262 loop over the active site.","method":"X-ray crystallography (2.35 Å); kinetic assays with pNPP substrate; site-directed mutagenesis (D262A)","journal":"Nature structural biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with mutagenesis and kinetic assays in a single rigorous study","pmids":["10048930"],"is_preprint":false},{"year":2004,"finding":"The cytoplasmic localization of MKP-3/DUSP6 is mediated by a CRM1-dependent nuclear export signal (NES) in its N-terminal noncatalytic domain; MKP-3 undergoes active nuclear-cytoplasmic shuttling. The NES and kinase interaction motif (KIM) function independently: KIM mutations abolish ERK2 binding without affecting localization, and NES mutations do not affect ERK2 binding or phosphatase activity. MKP-3 requires both a functional KIM and NES to cause cytoplasmic retention of ERK2.","method":"GFP-fusion live-cell imaging; leptomycin B treatment; domain deletion and point mutations; co-immunoprecipitation; FRAP/nuclear translocation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (LMB, mutagenesis, GFP imaging, co-IP), clear mechanistic dissection","pmids":["15269220"],"is_preprint":false},{"year":2005,"finding":"ERK2 phosphorylates MKP-3/DUSP6 on serines 159 and 197 in vitro and in vivo, promoting its proteasomal degradation in a MEK1/2-ERK1/2-dependent manner; double S159A/S197A mutants have ~3-fold longer half-life; this phosphorylation does not affect MKP-3 catalytic activity, constituting a positive feedback loop of ERKs on their own activity.","method":"In vitro phosphorylation assays with GST-MKP-3 fusion proteins; tetracycline-inducible cell lines; cycloheximide chase; proteasome inhibitor experiments; single and double serine mutant analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with mutagenesis confirmed in multiple cell-based systems, rigorous controls","pmids":["15632084"],"is_preprint":false},{"year":2007,"finding":"In mouse embryos, FGFR signaling is required for Dusp6 transcription; targeted inactivation of Dusp6 increases pERK levels and pERK target expression, demonstrating that DUSP6 acts as an in vivo negative feedback regulator of FGFR-ERK signaling during development.","method":"Conditional/targeted gene knockout in mice; immunohistochemistry for pERK; qRT-PCR; histological phenotype analysis","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with defined molecular readout (pERK elevation), confirmed by multiple phenotypic endpoints","pmids":["17164422"],"is_preprint":false},{"year":2003,"finding":"Pyst1/MKP3 expression in chick embryo neural plate and limb bud is induced downstream of FGF signaling via the MAPK cascade (blocked by FGFR inhibitor SU5402 or MEK inhibitor PD184352); overexpression of Pyst1 reduces activated MAPK levels, alters neural plate morphology, and retards limb bud outgrowth, demonstrating a negative feedback loop on FGF-MAPK signaling in vivo.","method":"Tissue transplantation/ablation; FGF protein application; pharmacological inhibitors (SU5402, PD184352); retroviral overexpression in chick embryos","journal":"Current biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vivo perturbations (genetic, pharmacological, protein application) converging on same conclusion","pmids":["12814546"],"is_preprint":false},{"year":2008,"finding":"FGF-induced DUSP6/MKP-3 transcription is driven by ERK1/2 signaling acting through a conserved Ets-factor binding site in the DUSP6 promoter; Ets2, a known ERK target, binds the endogenous DUSP6 promoter. The DUSP6 promoter-EGFP reporter recapitulates endogenous expression in chick neural plate dependent on FGFR, MAPK, and Ets-binding site integrity.","method":"Pharmacological inhibitors; promoter-reporter assays; ChIP; EGFP transgenic embryo experiments; mutagenesis of Ets-binding site","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP on endogenous promoter, mutagenesis, and in vivo reporter assays using multiple methods","pmids":["18321244"],"is_preprint":false},{"year":2008,"finding":"Dusp6-null mice show increased basal ERK1/2 phosphorylation in multiple tissues (heart, spleen, kidney, brain, fibroblasts) but no change in ERK5, p38, or JNK activation; loss of Dusp6 increases myocyte proliferation during cardiac development, resulting in cardiac hypercellularity protective against pressure overload and MI. Dusp6-/- MEFs show reduced apoptosis.","method":"Gene-targeted knockout mouse; western blotting; histology; cardiomyocyte proliferation assays; pressure-overload and MI models; MEF apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with multiple defined molecular (pERK specificity) and cellular (proliferation, apoptosis) readouts across multiple tissues and disease models","pmids":["18753132"],"is_preprint":false},{"year":2007,"finding":"DUSP6/MKP3 binds ERK1/2 in yeast and human cells but fails to bind ERK5; recombinant ERK2 activates DUSP6 catalytically whereas ERK5 cannot; DUSP6 dephosphorylates co-expressed ERK2 but not ERK5; DUSP6 blocks MEK1-driven ERK1/2 target transcription but not MEK5-driven ERK5 target transcription, confirming strict ERK1/2 specificity.","method":"Yeast two-hybrid; co-immunoprecipitation in human cells; in vitro catalytic activation assay; co-expression dephosphorylation assay; transcriptional reporter assays","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (yeast 2H, co-IP, in vitro assay, reporter) all converging on same conclusion","pmids":["18280112"],"is_preprint":false},{"year":2009,"finding":"BCI (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one is a small-molecule allosteric inhibitor of Dusp6 identified by zebrafish chemical screen; docking simulations predicted an allosteric binding site within the phosphatase domain; in vitro studies support a model in which BCI inhibits Dusp6 catalytic activation by blocking ERK2 substrate-induced activation.","method":"Transgenic zebrafish chemical screen; molecular docking; in vitro phosphatase activity assays with ERK2","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vivo screen, in vitro mechanistic assays, structural docking, multiple orthogonal validations","pmids":["19578332"],"is_preprint":false},{"year":2008,"finding":"The PI3K/mTOR pathway contributes to serum-induced phosphorylation and proteasomal degradation of DUSP6; amino acids and insulin/IGF-1 (mTOR agonists that do not activate ERK) also induce DUSP6 phosphorylation and degradation, requiring basal MEK activity; mutagenesis identified serine 159 as the specific mTOR pathway target on DUSP6.","method":"Pharmacological inhibitors (PI3K, mTOR, MEK); tetracycline-inducible cell lines; serine mutagenesis; cycloheximide chase; western blotting","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus pharmacological inhibitors in cell-based system, single lab","pmids":["18223677"],"is_preprint":false},{"year":2011,"finding":"DUSP6 mRNA stability is regulated by MEK/ERK signaling via the 3'UTR; hypoxia (HIF-1-dependent) also increases DUSP6 mRNA stability via the 3'UTR, requiring basal ERK activity; Tristetraprolin (TTP) and PUM2 reduce DUSP6 mRNA stability and expression.","method":"Luciferase 3'UTR reporter assays; mRNA stability assays with actinomycin D; pharmacological inhibitors; siRNA knockdown","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3'UTR reporter assays plus endogenous mRNA stability measurements, single lab, multiple methods","pmids":["20665674"],"is_preprint":false},{"year":2020,"finding":"DUSP6 dephosphorylates Drp1 at serine 616 independently of its known substrates ERK1/2, keeping Drp1-S616 phosphorylation low under normal conditions and preventing mitochondrial fragmentation and apoptosis. DUSP6 is SUMOylated at lysine 234 by SUMO1/2/3; SUMOylation maintains DUSP6 stability and catalytic function. Under oxidative stress, SENP1 is upregulated, causing deSUMOylation and DUSP6 degradation via ubiquitin-proteasome, leading to Drp1-S616 hyperphosphorylation and mitochondrial fragmentation; overexpression of WT but not the SUMOylation-deficient DUSP6-K234R mutant is protective.","method":"Co-immunoprecipitation; SUMOylation assays; phosphatase activity assays; site-directed mutagenesis (K234R); cell-based apoptosis assays; in vivo brain ischemia/reperfusion model","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, mutagenesis, in vitro and in vivo), identifies new substrate and PTM in a single rigorous study","pmids":["32232156"],"is_preprint":false},{"year":2012,"finding":"MKP-3/DUSP6 interacts with FOXO1 via residues 200–260 of MKP-3 and residues 360–456 of FOXO1; MKP-3 phosphatase activity (not the interaction itself) is required for FOXO1 nuclear translocation and gluconeogenic gene (G6Pase) transcription; ERK-phosphorylation-deficient FOXO1 loses interaction with MKP-3.","method":"Adenoviral overexpression; mutagenesis of MKP-3 and FOXO1; co-immunoprecipitation; glucose output assays; in vivo liver knockdown rescue experiments","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain mapping by mutagenesis and co-IP, in vivo rescue, single lab","pmids":["22848439"],"is_preprint":false},{"year":2012,"finding":"DUSP6 depletion in AML cells harboring FLT3-ITD reduces ERK1/2 dephosphorylation and attenuates FLT3-ITD-dependent cell proliferation; high DUSP6 expression in FLT3-ITD cells is causally dependent on FLT3-ITD kinase activity and ERK signaling (shown by pharmacological inhibition and siRNA knockdown).","method":"siRNA/shRNA knockdown; pharmacological FLT3 and ERK inhibitors; proliferation assays; western blotting","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — siRNA plus pharmacological inhibitors, multiple cell lines, single lab","pmids":["22784513"],"is_preprint":false},{"year":2013,"finding":"PR-B interacts with DUSP6 via a common docking (CD) domain in PR-B N-terminus; DUSP6 acts as a scaffold for CK2-dependent phosphorylation of PR-B at Ser81, which is required for recruitment of a PR-B/DUSP6/CK2 transcriptional complex to the Wnt1 enhancer and expression of STAT5A and Wnt1 target genes in breast cancer cells.","method":"Binding studies (Co-IP/pulldown); CD domain mutagenesis; ChIP; luciferase reporter assays; western blotting","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, mutagenesis, and ChIP, single lab","pmids":["23921636"],"is_preprint":false},{"year":2018,"finding":"PKN2 phosphorylates and activates DUSP6 through direct association, as confirmed by co-immunoprecipitation and kinase activity assay; activated DUSP6 suppresses ERK1/2 activation, thereby reducing IL-4 and IL-10 expression from colon cancer cells and inhibiting M2 macrophage polarization.","method":"Co-immunoprecipitation; kinase activity assay; luciferase assay; ChIP-qPCR; siRNA knockdown; in vitro/in vivo tumor models","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and kinase assay establishing direct interaction and activation, multiple functional readouts, single lab","pmids":["29368606"],"is_preprint":false},{"year":2008,"finding":"DUSP6 transcription in human pancreatic cancer cells is regulated by MAPK1/ERK2 through an ETS transcription factor binding site in intron 1, with ETS2 specifically associating with this region; this constitutes a feedback loop where MAPK1 drives its own negative regulator's expression.","method":"Promoter-reporter assays; ChIP; pharmacological inhibitor experiments; mutagenesis of ETS binding site","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP on endogenous locus plus reporter mutagenesis, single lab","pmids":["18848526"],"is_preprint":false},{"year":2010,"finding":"DUSP6 overexpression in corneal epithelial cells prevents ERK1/2 phosphorylation and reduces proliferation rates by >50%; this establishes a functional link between DUSP6-mediated ERK dephosphorylation and control of epithelial cell proliferation.","method":"Lentiviral overexpression; immunoblotting; [3H]-thymidine proliferation assays","journal":"Molecular vision","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct overexpression with functional proliferation readout, but single lab and single method for DUSP6 OE","pmids":["20806045"],"is_preprint":false},{"year":2020,"finding":"The transcriptional repressor CIC directly represses DUSP6 transcription by binding three cis-regulatory elements (CREs) in the DUSP6 promoter. ERK1/2 activates p90RSK, which phosphorylates CIC at S173 and S301, creating a 14-3-3 recognition motif that promotes nuclear export of CIC, thereby derepressing DUSP6 transcription.","method":"ChIP; promoter-reporter assays; mutagenesis; co-immunoprecipitation; 14-3-3 binding assays","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and mutagenesis plus Co-IP, single lab, mechanistically detailed","pmids":["33103082"],"is_preprint":false},{"year":2012,"finding":"miR-181a directly represses DUSP6 protein expression in naive CD4+ T cells; age-associated decline in miR-181a increases DUSP6 protein, which dephosphorylates ERK after TCR stimulation, impairing T cell activation. Reconstitution of miR-181a or siRNA knockdown of DUSP6 restores ERK phosphorylation and T cell responses; allosteric DUSP6 inhibition (BCI) similarly improves TCR-induced ERK signaling.","method":"miRNA reconstitution; siRNA knockdown; western blotting; flow cytometry; proliferation and activation marker assays; pharmacological inhibition","journal":"Nature medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple knockdown approaches with functional readouts, but no direct binding assay for miR-181a/DUSP6","pmids":["23023500"],"is_preprint":false},{"year":2018,"finding":"DUSP6 deficiency in T cells leads to enhanced JNK and p38 phosphorylation but impaired glycolysis; DUSP6-/- T cells cannot induce phosphofructokinase activity and rely on fatty acid oxidation; JNK/p38 inhibitors reduce IL-21 production but do not restore glycolysis, indicating DUSP6 connects TCR signaling to metabolic commitment toward glycolysis separately from TFH cytokine regulation.","method":"DUSP6-/- mouse model; metabolic assays (glycolysis, phosphofructokinase activity, fatty acid oxidation); phospho-kinase western blotting; pharmacological JNK/p38 inhibitors; in vivo immunization","journal":"PNAS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO with metabolic and signaling readouts, single lab","pmids":["30087184"],"is_preprint":false},{"year":2021,"finding":"DUSP6 directly dephosphorylates SMAD2, and immunoprecipitation confirmed this interaction; DUSP6-mediated ERK2 and SMAD2 dephosphorylation regulates nuclear translocation of NFATC1 and inhibits osteoclast differentiation.","method":"Co-immunoprecipitation; western blotting; ERK2-deficient BMM analysis; DUSP6 overexpression and siRNA knockdown; in vitro osteoclastogenesis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and functional assays establish SMAD2 as a DUSP6 substrate, single lab","pmids":["34475393"],"is_preprint":false},{"year":2022,"finding":"In neutrophils, DUSP6 is transcriptionally activated by p38-C/EBPβ signaling and acts as an effector maintaining p-p38 activity by downregulating pERK and p38-targeting phosphatases DUSP1/DUSP16; neutrophil-specific Dusp6 knockout attenuates cardiac damage after myocardial infarction.","method":"Rat nonsense-mutation strain; bone marrow transplantation; neutrophil-specific conditional KO mice; neutrophil-cardiomyocyte co-culture; western blotting; cardiac functional measurements","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic models (global and cell-specific KO, BMT) with defined pathway readouts, single lab","pmids":["36335128"],"is_preprint":false},{"year":2022,"finding":"DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression; ectopic DUSP6 expression exacerbated disease in PDX models; pharmacological DUSP6 inhibition reduced S6 kinase and JAK-STAT signaling and suppressed inflammatory cytokine production, defining a DUSP6-RSK1 axis.","method":"Single-cell RNA-seq; DUSP6 ectopic expression in PDX models; pharmacological DUSP6 inhibition; Jak2V617F and MPLW515L MPN mouse models; western blotting for S6 and JAK-STAT pathway components","journal":"Nature cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo PDX and mouse models with defined signaling readouts, single lab","pmids":["36581736"],"is_preprint":false},{"year":2021,"finding":"FBXO31 is the substrate receptor of CRL1 ubiquitin ligase that promotes ubiquitylation-mediated degradation of DUSP6; depletion of FBXO31 stabilizes DUSP6, suppresses ERK signaling, and paradoxically activates PI3K-AKT signaling; BCI treatment of FBXO31-depleted cells suppresses AKT activation and prevents tumor formation, indicating tumor suppressor activity of FBXO31 is DUSP6-dependent.","method":"Co-immunoprecipitation; ubiquitylation assays; shRNA depletion; western blotting; mouse orthotopic tumor model; pharmacological inhibition with BCI","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ubiquitylation assays identify FBXO31 as DUSP6 E3 ligase, in vivo rescue with BCI, single lab","pmids":["34686346"],"is_preprint":false},{"year":2021,"finding":"TRIM65 promotes ubiquitination and degradation of DUSP6, resulting in ERK1/2 activation and C-myc induction in endometrial stromal cells; C-myc in turn promotes TRIM65 expression, creating a feedback loop; ERK1/2 inhibition reverses these effects in vivo.","method":"Co-immunoprecipitation; ubiquitylation assay; dual luciferase assay; ChIP; western blotting; in vivo mouse EM model","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and ubiquitylation assays identify TRIM65 as DUSP6 E3 ligase, in vivo validation, single lab","pmids":["33146694"],"is_preprint":false},{"year":2014,"finding":"MEF2D functions as a p38MAPK-dependent transcriptional repressor of Dusp6 in skeletal myoblasts; MEF2A binds the Dusp6 genomic locus (identified by ChIP-exo); siRNA targeting MEF2A/D reveals divergent regulation of Dusp6 in cardiac versus skeletal myogenic lineages.","method":"ChIP-exo; RNA-seq of MEF2A-depleted cells; siRNA knockdown; promoter-reporter assays; pharmacological p38 inhibition","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-exo plus RNA-seq and siRNA in multiple cell types, single lab","pmids":["25217591"],"is_preprint":false},{"year":2018,"finding":"DUSP6 promotes endothelial inflammation by facilitating TNF-α-induced ICAM-1 expression through canonical NF-κB-mediated transcription, independently of ERK signaling; DUSP6 knockout mice show reduced ICAM-1 in aorta/vein and reduced neutrophil recruitment and susceptibility to lung injury in sepsis models.","method":"DUSP6 knockout mice; RNAi in HUVECs; ICAM-1 reporter assays; NF-κB pathway analysis; LPS/TNF-α sepsis model","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mice plus RNAi with in vivo and in vitro functional readouts, single lab; ERK-independence determined by pharmacological methods","pmids":["29493888"],"is_preprint":false},{"year":2011,"finding":"In oligodendrocytes, DUSP6 overexpression increases AMPA receptor-induced inward currents and cytosolic calcium overload, while blocking DUSP6 expression (enhancing ERK1/2 phosphorylation) significantly reduces AMPA receptor-induced oligodendrocyte death; ERK pathway inhibition (UO126) potentiates excitotoxic death and increases mitochondrial dysfunction, demonstrating that DUSP6-controlled ERK levels regulate AMPA receptor permeability and oligodendroglial excitotoxicity.","method":"Microarray and qPCR; DUSP6 knockdown; pharmacological MAPK/ERK inhibition (UO126); patch-clamp electrophysiology; calcium imaging; cell death assays; in vivo optic nerve analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods including electrophysiology and cell death assays, single lab","pmids":["21300799"],"is_preprint":false},{"year":2013,"finding":"MKP-3/DUSP6 is required for normal resolution of acute postoperative pain; MKP-3 knockout mice develop persistent mechanical allodynia with sustained spinal pERK and p-p38 (in neurons and microglia); pharmacological inhibition of ERK or p38 reduced persistent allodynia in KO mice, demonstrating DUSP6 normally terminates MAPK activity to resolve pain.","method":"MKP-3 KO mice; paw incision pain model; behavioral allodynia assays; western blotting for pERK/p-p38; pharmacological MAPK inhibitors; immunofluorescence","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO with behavioral and molecular readouts, single lab","pmids":["24155322"],"is_preprint":false},{"year":2019,"finding":"In DBA/2J mice, a Met62Ile substitution in DUSP6 reduces the interaction between DUSP6 and ERK, resulting in increased ERK phosphorylation and activity; this hypomorphic allele acts as a genetic modifier of body mass in muscular dystrophy through enhanced ERK activity.","method":"Whole-genome sequencing; RNA-seq; co-immunoprecipitation to measure ERK binding; pharmacological DUSP6 inhibition in myoblasts; ERK phosphorylation assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — natural variant mapped to DUSP6-ERK interface by Co-IP, functional verification by kinase assays and inhibitor experiments, single lab","pmids":["30289454"],"is_preprint":false},{"year":2000,"finding":"Nitric oxide downregulates MKP-3/DUSP6 by destabilizing its mRNA, leading to decreased MKP-3 protein levels and protection of ERK1/2 from TNFα-induced dephosphorylation in endothelial cells; this protects Bcl-2 from proteolysis and prevents cytochrome c release. NO does not affect MKP-3 phosphatase activity directly.","method":"Northern blotting; western blotting; NO donor treatment; MKP-3 overexpression; Bcl-2/cytochrome c measurements","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — mRNA stability and protein level experiments with functional apoptosis readouts, NO independence of phosphatase activity tested by overexpression, single lab","pmids":["10846176"],"is_preprint":false},{"year":2014,"finding":"FOXO1-dependent upregulation of MKP-3/DUSP6 mediates glucocorticoid-induced hepatic lipid accumulation; dexamethasone increases MKP-3 protein in hepatoma cells and mouse liver via FOXO1 (FOXO1 knockdown or dominant-negative FOXO1 blocks this); MKP-3 deficient mice are protected from glucocorticoid-induced metabolic side effects.","method":"FOXO1 siRNA knockdown; dominant-negative FOXO1 overexpression; MKP-3 KO mice; western blotting; metabolic phenotyping","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic perturbations (siRNA, DN overexpression, KO) with consistent metabolic readouts, single lab","pmids":["24946098"],"is_preprint":false},{"year":2004,"finding":"Drosophila MKP-3 (DMKP-3) specifically binds DERK via its N-terminal ERK-binding domain and suppresses Ras/DERK pathway signaling in vivo; DMKP-3 null mutants show embryonic lethality, severe oogenesis defects, extra photoreceptor cells and wing veins phenocopying gain-of-function DERK mutants; genetic interactions confirm DMKP-3 is indispensable for DERK signaling regulation.","method":"Drosophila genetics (null mutants, hypomorphs, overexpression transgenes); genetic interaction analysis with Ras/ERK pathway mutants; in vivo epistasis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple alleles (null, hypomorph, OE) with strong genetic epistasis analysis, ortholog of DUSP6 with consistent domain architecture","pmids":["14701731"],"is_preprint":false}],"current_model":"DUSP6/MKP-3 is a cytoplasmic, CRM1-dependent dual-specificity phosphatase that is allosterically activated upon direct binding of ERK1/2 to its N-terminal noncatalytic domain (via a kinase interaction motif), causing closure of a Asp262 loop over the active site to enhance catalytic efficiency; activated DUSP6 then dephosphorylates the TEY motif of ERK1/2 (but not ERK5, JNK, or p38) to terminate MAPK signaling; ERK1/2 in turn phosphorylates DUSP6 at Ser159 and Ser197 to promote its proteasomal degradation (positive feedback on ERK activity) and drives DUSP6 transcription via an Ets2/ETS binding site in the DUSP6 promoter (negative feedback); additional regulation is imposed by mTOR-dependent phosphorylation of Ser159, SUMOylation at Lys234 (stabilizing the protein), ubiquitin ligases FBXO31 and TRIM65 (promoting degradation), and miR-181a (repressing translation); beyond ERK1/2, DUSP6 also dephosphorylates Drp1-Ser616 to limit mitochondrial fission, interacts with FOXO1 to promote hepatic gluconeogenesis, and scaffolds CK2-dependent phosphorylation of progesterone receptor-B, demonstrating phosphatase-independent scaffolding functions in addition to its canonical role as a cytoplasmic ERK1/2 feedback attenuator downstream of FGF and other receptor tyrosine kinase signals."},"narrative":{"mechanistic_narrative":"DUSP6 (MKP-3/Pyst1) is a cytoplasmic dual-specificity phosphatase that serves as the principal negative-feedback attenuator of ERK1/2 MAP kinase signaling downstream of FGF and other receptor tyrosine kinase inputs [PMID:8670865, PMID:17164422, PMID:12814546]. It selectively dephosphorylates and inactivates ERK1/2 while displaying very low activity toward JNK, p38, and ERK5 [PMID:8670865, PMID:8910287, PMID:18280112], and forms a physical complex with MAP kinase in cells [PMID:8670865]. DUSP6 is catalytically inert until ERK2 binds its N-terminal noncatalytic domain through a kinase interaction motif; this binding allosterically activates the phosphatase independently of ERK kinase activity by inducing closure of the Asp262 loop over the distorted active site, as resolved by crystallography and kinetic analysis [PMID:9596579, PMID:10048930]. Cytoplasmic retention of both DUSP6 and its bound ERK2 substrate depends on a CRM1-dependent nuclear export signal in the N-terminal domain that functions independently of the kinase interaction motif [PMID:15269220]. The enzyme is embedded in interlocking feedback circuits: ERK1/2 drives DUSP6 transcription through Ets-factor binding sites in the promoter and intron 1 (negative feedback) [PMID:18321244, PMID:18848526], while ERK-mediated phosphorylation of DUSP6 at Ser159/Ser197 targets it for proteasomal degradation (positive feedback on ERK activity) [PMID:15632084]. Genetic ablation in mice and Drosophila elevates phospho-ERK and produces developmental and proliferative phenotypes, confirming its in vivo role in restraining the Ras/ERK pathway [PMID:17164422, PMID:18753132, PMID:14701731]. Beyond ERK1/2, DUSP6 dephosphorylates Drp1-Ser616 to limit mitochondrial fission and apoptosis, an activity gated by SUMOylation at Lys234 [PMID:32232156], and also dephosphorylates SMAD2 [PMID:34475393]. It additionally performs phosphatase-dependent and scaffolding functions independent of ERK catalysis, including interaction with FOXO1 to drive hepatic gluconeogenic gene expression [PMID:22848439] and scaffolding of CK2-dependent PR-B phosphorylation at a Wnt1 enhancer [PMID:23921636].","teleology":[{"year":1996,"claim":"Established that DUSP6 is a cytoplasmic dual-specificity phosphatase with selectivity for ERK over JNK/p38, defining its core enzymatic identity and substrate preference.","evidence":"Subcellular fractionation, in vitro and in vivo phosphatase assays, and co-IP in transfected COS/Cos-1 cells","pmids":["8670865","8626780","8910287"],"confidence":"High","gaps":["Mechanism of ERK selectivity at the molecular level not yet resolved","Did not address how catalytic activity is regulated"]},{"year":1998,"claim":"Resolved that DUSP6 is catalytically dormant until ERK2 binds its noncatalytic N-terminus, revealing substrate-induced allosteric activation as the activation mechanism.","evidence":"In vitro binding and phosphatase assays with purified recombinant proteins and the D319N ERK2 mutant","pmids":["9596579"],"confidence":"High","gaps":["Structural basis of allosteric activation not yet defined","Did not map the binding motif residues"]},{"year":1999,"claim":"Provided the structural mechanism of allosteric activation by showing ERK2 binding closes the Asp262 loop over a distorted active site to render the catalytic domain competent.","evidence":"2.35 Å crystal structure of the catalytic domain with kinetic assays and D262A mutagenesis","pmids":["10048930"],"confidence":"High","gaps":["No co-crystal of the full-length DUSP6-ERK2 complex","Conformational dynamics of the loop closure inferred rather than directly observed"]},{"year":2004,"claim":"Distinguished the CRM1-dependent nuclear export signal from the kinase interaction motif, explaining how DUSP6 enforces cytoplasmic retention of ERK2.","evidence":"GFP live-cell imaging, leptomycin B, domain mutagenesis, and co-IP in cells","pmids":["15269220"],"confidence":"High","gaps":["Import pathway / shuttling regulators not identified","Physiological signals that modulate shuttling unknown"]},{"year":2003,"claim":"Demonstrated in vivo that FGF-MAPK signaling induces DUSP6 expression and that DUSP6 feeds back to suppress MAPK, establishing the developmental negative-feedback loop.","evidence":"Tissue manipulation, FGF protein application, FGFR/MEK inhibitors, and retroviral overexpression in chick embryos","pmids":["12814546"],"confidence":"High","gaps":["Promoter elements mediating induction not yet mapped","Did not establish degradation-based feedback"]},{"year":2005,"claim":"Identified ERK-mediated Ser159/Ser197 phosphorylation as a degron signal, defining a positive-feedback arm where ERK destabilizes its own phosphatase.","evidence":"In vitro kinase assays, inducible cell lines, cycloheximide chase, and serine mutant analysis","pmids":["15632084"],"confidence":"High","gaps":["E3 ligase for ERK-triggered degradation not identified in this study","Quantitative impact on overall ERK dynamics not modeled"]},{"year":2007,"claim":"Confirmed via mammalian and Drosophila genetics that DUSP6 is an indispensable in vivo negative regulator of FGFR/Ras-ERK signaling during development.","evidence":"Targeted Dusp6 knockout in mice with pERK IHC/qRT-PCR; Drosophila DMKP-3 null and epistasis analysis","pmids":["17164422","14701731"],"confidence":"High","gaps":["Tissue-specific contributions only partly resolved","Compensation by other DUSPs not fully addressed"]},{"year":2008,"claim":"Mapped the transcriptional feedback to Ets-factor binding sites (promoter and intron 1) bound by Ets2, and showed tissue-wide pERK specificity in knockouts with proliferative/apoptotic consequences.","evidence":"ChIP, promoter-reporter mutagenesis, EGFP transgenics, and gene-targeted KO mice with cardiac phenotyping","pmids":["18321244","18848526","18753132"],"confidence":"High","gaps":["Combinatorial control with repressors not yet integrated","Mechanism of proliferation/apoptosis effects downstream of pERK incompletely defined"]},{"year":2008,"claim":"Extended DUSP6 regulation beyond ERK by implicating mTOR-dependent Ser159 phosphorylation and 3'UTR-mediated mRNA stability control.","evidence":"PI3K/mTOR/MEK inhibitors with serine mutagenesis; 3'UTR luciferase and actinomycin D mRNA stability assays with TTP/PUM2 knockdown","pmids":["18223677","20665674"],"confidence":"Medium","gaps":["mTOR-responsive kinase acting on Ser159 not identified","Single-lab findings without independent replication"]},{"year":2009,"claim":"Validated DUSP6 as a druggable target by identifying BCI, a small-molecule allosteric inhibitor that blocks ERK2-induced catalytic activation.","evidence":"Transgenic zebrafish chemical screen, molecular docking, and in vitro phosphatase assays","pmids":["19578332"],"confidence":"High","gaps":["Exact BCI binding site confirmed only by docking","Selectivity across other DUSPs not fully characterized"]},{"year":2012,"claim":"Uncovered phosphatase-dependent non-ERK functions and additional upstream regulators, showing DUSP6 interacts with FOXO1 to drive gluconeogenesis and is repressed by miR-181a in T cells.","evidence":"Domain-mapping co-IP, adenoviral/in vivo liver rescue (FOXO1); miRNA reconstitution and siRNA with functional T-cell readouts (miR-181a)","pmids":["22848439","23023500","22784513"],"confidence":"Medium","gaps":["No direct miR-181a/DUSP6 binding assay","FOXO1 interaction findings from a single lab"]},{"year":2013,"claim":"Revealed scaffolding (phosphatase-independent) activity in which DUSP6 organizes CK2-dependent phosphorylation of PR-B to activate Wnt1 target transcription.","evidence":"Co-IP/pulldown, common-docking domain mutagenesis, ChIP, and luciferase reporters in breast cancer cells","pmids":["23921636"],"confidence":"Medium","gaps":["Single-lab finding without reciprocal validation","Structural basis of the scaffolding complex unknown"]},{"year":2014,"claim":"Extended transcriptional control to repressive inputs (MEF2A/D, p38-dependent) and demonstrated FOXO1-driven DUSP6 upregulation in glucocorticoid-induced hepatic lipid accumulation.","evidence":"ChIP-exo, RNA-seq, siRNA/dominant-negative FOXO1, and KO mouse metabolic phenotyping","pmids":["25217591","24946098"],"confidence":"Medium","gaps":["Lineage-specific divergence of MEF2 regulation mechanistically unresolved","Single-lab findings"]},{"year":2020,"claim":"Defined a non-ERK substrate (Drp1-Ser616) and a stabilizing PTM, showing SUMOylation at Lys234 maintains DUSP6 stability/activity and that SENP1-driven deSUMOylation under oxidative stress promotes mitochondrial fragmentation.","evidence":"Co-IP, SUMOylation and phosphatase assays, K234R mutagenesis, and in vivo brain ischemia/reperfusion model","pmids":["32232156"],"confidence":"High","gaps":["Selectivity of DUSP6 between ERK and Drp1 substrates not mechanistically partitioned","SUMO ligase identity not defined"]},{"year":2021,"claim":"Identified two E3 ligases (FBXO31, TRIM65) controlling DUSP6 turnover and additional substrate (SMAD2), expanding the degradation network and substrate repertoire.","evidence":"Co-IP, ubiquitylation assays, shRNA depletion, in vivo tumor/endometrial models (FBXO31, TRIM65); co-IP and osteoclastogenesis assays (SMAD2)","pmids":["34686346","33146694","34475393"],"confidence":"Medium","gaps":["Relationship between FBXO31- and TRIM65-mediated degradation not reconciled","Single-lab findings per ligase"]},{"year":2022,"claim":"Placed DUSP6 in disease-context signaling axes, including JAK2-inhibitor resistance via a DUSP6-RSK1 axis and neutrophil p38-C/EBPβ-driven DUSP6 maintaining p-p38 after myocardial infarction.","evidence":"scRNA-seq, PDX and MPN mouse models, pharmacological DUSP6 inhibition; neutrophil-specific conditional KO and co-culture","pmids":["36581736","36335128"],"confidence":"Medium","gaps":["Direct enzymatic targets in these contexts not all defined","Single-lab findings"]},{"year":null,"claim":"How DUSP6 partitions its catalytic and scaffolding activities among ERK1/2, Drp1, SMAD2, and protein complexes such as PR-B/CK2 within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model for substrate selection beyond ERK","Spatial/temporal regulation of non-ERK substrate engagement unknown","Structural basis of scaffolding complexes not determined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,3,11,15,25]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,4,15]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,7,8]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[16,18]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,2,5]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,7,8,11]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,8,37]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[6,28,29]}],"complexes":[],"partners":["MAPK1","MAPK3","FOXO1","PKN2","FBXO31","TRIM65","SMAD2","DNM1L"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16828","full_name":"Dual specificity protein phosphatase 6","aliases":["Dual specificity protein phosphatase PYST1","Mitogen-activated protein kinase phosphatase 3","MAP kinase phosphatase 3","MKP-3"],"length_aa":381,"mass_kda":42.3,"function":"Dual specificity protein phosphatase, which mediates dephosphorylation and inactivation of MAP kinases (PubMed:8670865). Has a specificity for the ERK family (PubMed:8670865). Plays an important role in alleviating chronic postoperative pain (By similarity). Necessary for the normal dephosphorylation of the long-lasting phosphorylated forms of spinal MAPK1/3 and MAP kinase p38 induced by peripheral surgery, which drives the resolution of acute postoperative allodynia (By similarity). Also important for dephosphorylation of MAPK1/3 in local wound tissue, which further contributes to resolution of acute pain (By similarity). Promotes cell differentiation by regulating MAPK1/MAPK3 activity and regulating the expression of AP1 transcription factors (PubMed:29043977)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q16828/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DUSP6","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/DUSP6","total_profiled":1310},"omim":[{"mim_id":"617191","title":"p38-INHIBITED CUTANEOUS SQUAMOUS CELL CARCINOMA-ASSOCIATED LONG INTERGENIC NONCODING RNA; PICSAR","url":"https://www.omim.org/entry/617191"},{"mim_id":"615269","title":"HYPOGONADOTROPIC HYPOGONADISM 19 WITH OR WITHOUT ANOSMIA; HH19","url":"https://www.omim.org/entry/615269"},{"mim_id":"615266","title":"HYPOGONADOTROPIC HYPOGONADISM 17 WITH OR WITHOUT ANOSMIA; HH17","url":"https://www.omim.org/entry/615266"},{"mim_id":"607984","title":"SPROUTY RTK SIGNALING ANTAGONIST 4; SPRY4","url":"https://www.omim.org/entry/607984"},{"mim_id":"602749","title":"DUAL-SPECIFICITY PHOSPHATASE 7; DUSP7","url":"https://www.omim.org/entry/602749"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"salivary gland","ntpm":213.0}],"url":"https://www.proteinatlas.org/search/DUSP6"},"hgnc":{"alias_symbol":["MKP-3","PYST1"],"prev_symbol":[]},"alphafold":{"accession":"Q16828","domains":[{"cath_id":"3.40.250.10","chopping":"16-148","consensus_level":"high","plddt":77.6868,"start":16,"end":148},{"cath_id":"3.90.190.10","chopping":"207-346","consensus_level":"high","plddt":94.6342,"start":207,"end":346}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16828","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16828-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16828-F1-predicted_aligned_error_v6.png","plddt_mean":75.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DUSP6","jax_strain_url":"https://www.jax.org/strain/search?query=DUSP6"},"sequence":{"accession":"Q16828","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16828.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16828/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16828"}},"corpus_meta":[{"pmid":"9596579","id":"PMC_9596579","title":"Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9596579","citation_count":439,"is_preprint":false},{"pmid":"8670865","id":"PMC_8670865","title":"Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8670865","citation_count":359,"is_preprint":false},{"pmid":"8626780","id":"PMC_8626780","title":"MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8626780","citation_count":320,"is_preprint":false},{"pmid":"8910287","id":"PMC_8910287","title":"The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8910287","citation_count":319,"is_preprint":false},{"pmid":"23023500","id":"PMC_23023500","title":"Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23023500","citation_count":297,"is_preprint":false},{"pmid":"17164422","id":"PMC_17164422","title":"Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development.","date":"2007","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17164422","citation_count":235,"is_preprint":false},{"pmid":"19578332","id":"PMC_19578332","title":"Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages.","date":"2009","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/19578332","citation_count":209,"is_preprint":false},{"pmid":"23643382","id":"PMC_23643382","title":"Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23643382","citation_count":202,"is_preprint":false},{"pmid":"12759238","id":"PMC_12759238","title":"Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer.","date":"2003","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12759238","citation_count":191,"is_preprint":false},{"pmid":"18321244","id":"PMC_18321244","title":"Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter.","date":"2008","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/18321244","citation_count":166,"is_preprint":false},{"pmid":"20097731","id":"PMC_20097731","title":"Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.","date":"2010","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20097731","citation_count":160,"is_preprint":false},{"pmid":"18753132","id":"PMC_18753132","title":"DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18753132","citation_count":152,"is_preprint":false},{"pmid":"12814546","id":"PMC_12814546","title":"Negative feedback regulation of FGF signaling levels by Pyst1/MKP3 in chick embryos.","date":"2003","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/12814546","citation_count":150,"is_preprint":false},{"pmid":"10048930","id":"PMC_10048930","title":"Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation.","date":"1999","source":"Nature structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/10048930","citation_count":140,"is_preprint":false},{"pmid":"29368606","id":"PMC_29368606","title":"PKN2 in colon cancer cells inhibits M2 phenotype polarization of tumor-associated macrophages via regulating DUSP6-Erk1/2 pathway.","date":"2018","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29368606","citation_count":122,"is_preprint":false},{"pmid":"15632084","id":"PMC_15632084","title":"Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15632084","citation_count":118,"is_preprint":false},{"pmid":"15824892","id":"PMC_15824892","title":"Abrogation of DUSP6 by hypermethylation in human pancreatic cancer.","date":"2005","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15824892","citation_count":113,"is_preprint":false},{"pmid":"10846176","id":"PMC_10846176","title":"Nitric oxide down-regulates MKP-3 mRNA levels: involvement in endothelial cell protection from apoptosis.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10846176","citation_count":112,"is_preprint":false},{"pmid":"15269220","id":"PMC_15269220","title":"Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15269220","citation_count":112,"is_preprint":false},{"pmid":"9788880","id":"PMC_9788880","title":"Isolation of the human genes encoding the pyst1 and Pyst2 phosphatases: characterisation of Pyst2 as a cytosolic dual-specificity MAP kinase phosphatase and its catalytic activation by both MAP and SAP kinases.","date":"1998","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/9788880","citation_count":110,"is_preprint":false},{"pmid":"29545965","id":"PMC_29545965","title":"Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer.","date":"2018","source":"Cancer biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29545965","citation_count":107,"is_preprint":false},{"pmid":"15832194","id":"PMC_15832194","title":"Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.","date":"2005","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/15832194","citation_count":103,"is_preprint":false},{"pmid":"19608870","id":"PMC_19608870","title":"Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.","date":"2009","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19608870","citation_count":98,"is_preprint":false},{"pmid":"21499306","id":"PMC_21499306","title":"Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21499306","citation_count":87,"is_preprint":false},{"pmid":"18280112","id":"PMC_18280112","title":"DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5.","date":"2007","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18280112","citation_count":76,"is_preprint":false},{"pmid":"28242024","id":"PMC_28242024","title":"Enhancement of macrophage inflammatory responses by CCL2 is correlated with increased miR-9 expression and downregulation of the ERK1/2 phosphatase Dusp6.","date":"2017","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28242024","citation_count":75,"is_preprint":false},{"pmid":"29050982","id":"PMC_29050982","title":"Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29050982","citation_count":74,"is_preprint":false},{"pmid":"21387288","id":"PMC_21387288","title":"Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21387288","citation_count":70,"is_preprint":false},{"pmid":"25217591","id":"PMC_25217591","title":"Global MEF2 target gene analysis in cardiac and skeletal muscle reveals novel regulation of DUSP6 by p38MAPK-MEF2 signaling.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25217591","citation_count":70,"is_preprint":false},{"pmid":"9858808","id":"PMC_9858808","title":"Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer.","date":"1998","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9858808","citation_count":70,"is_preprint":false},{"pmid":"32232156","id":"PMC_32232156","title":"DUSP6 SUMOylation protects cells from oxidative damage via direct regulation of Drp1 dephosphorylation.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32232156","citation_count":68,"is_preprint":false},{"pmid":"18223677","id":"PMC_18223677","title":"Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18223677","citation_count":67,"is_preprint":false},{"pmid":"20665674","id":"PMC_20665674","title":"Post-transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling and hypoxia.","date":"2011","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20665674","citation_count":65,"is_preprint":false},{"pmid":"30936125","id":"PMC_30936125","title":"Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30936125","citation_count":65,"is_preprint":false},{"pmid":"11104676","id":"PMC_11104676","title":"Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells.","date":"2000","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11104676","citation_count":61,"is_preprint":false},{"pmid":"29444893","id":"PMC_29444893","title":"Dusp6 attenuates Ras/MAPK signaling to limit zebrafish heart regeneration.","date":"2018","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29444893","citation_count":59,"is_preprint":false},{"pmid":"24722245","id":"PMC_24722245","title":"Mitogen-activated protein kinase phosphatase 3 (MKP-3)-deficient mice are resistant to diet-induced obesity.","date":"2014","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24722245","citation_count":58,"is_preprint":false},{"pmid":"31557398","id":"PMC_31557398","title":"Long non-coding RNA TUG1 promotes airway remodelling by suppressing the miR-145-5p/DUSP6 axis in cigarette smoke-induced COPD.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31557398","citation_count":56,"is_preprint":false},{"pmid":"28910386","id":"PMC_28910386","title":"DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28910386","citation_count":55,"is_preprint":false},{"pmid":"30087184","id":"PMC_30087184","title":"DUSP6 mediates T cell receptor-engaged glycolysis and restrains TFH cell differentiation.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30087184","citation_count":51,"is_preprint":false},{"pmid":"11960712","id":"PMC_11960712","title":"Expression of the ERK-specific MAP kinase phosphatase PYST1/MKP3 in mouse embryos during morphogenesis and early organogenesis.","date":"2002","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/11960712","citation_count":50,"is_preprint":false},{"pmid":"23132790","id":"PMC_23132790","title":"DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.","date":"2013","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23132790","citation_count":50,"is_preprint":false},{"pmid":"36581736","id":"PMC_36581736","title":"DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression.","date":"2022","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36581736","citation_count":48,"is_preprint":false},{"pmid":"20554528","id":"PMC_20554528","title":"Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20554528","citation_count":47,"is_preprint":false},{"pmid":"23965468","id":"PMC_23965468","title":"A missense mutation in DUSP6 is associated with Class III malocclusion.","date":"2013","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/23965468","citation_count":45,"is_preprint":false},{"pmid":"18848526","id":"PMC_18848526","title":"Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18848526","citation_count":44,"is_preprint":false},{"pmid":"11701771","id":"PMC_11701771","title":"Two kinds of mitogen-activated protein kinase phosphatases, MKP-1 and MKP-3, are differentially activated by acute and chronic methamphetamine treatment in the rat brain.","date":"2001","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11701771","citation_count":44,"is_preprint":false},{"pmid":"20650883","id":"PMC_20650883","title":"p-MAPK1/3 and DUSP6 regulate epididymal cell proliferation and survival in a region-specific manner in mice.","date":"2010","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/20650883","citation_count":43,"is_preprint":false},{"pmid":"25477247","id":"PMC_25477247","title":"Hepatitis C virus-induced reduction in miR-181a impairs CD4(+) T-cell responses through overexpression of DUSP6.","date":"2015","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/25477247","citation_count":43,"is_preprint":false},{"pmid":"34098264","id":"PMC_34098264","title":"Hydrogen sulfide exposure induces pyroptosis in the trachea of broilers via the regulatory effect of circRNA-17828/miR-6631-5p/DUSP6 crosstalk on ROS production.","date":"2021","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/34098264","citation_count":43,"is_preprint":false},{"pmid":"22784513","id":"PMC_22784513","title":"Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression.","date":"2012","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/22784513","citation_count":41,"is_preprint":false},{"pmid":"23921636","id":"PMC_23921636","title":"A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/23921636","citation_count":41,"is_preprint":false},{"pmid":"36335128","id":"PMC_36335128","title":"Dusp6 deficiency attenuates neutrophil-mediated cardiac damage in the acute inflammatory phase of myocardial infarction.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36335128","citation_count":40,"is_preprint":false},{"pmid":"21471446","id":"PMC_21471446","title":"CD40-modulated dual-specificity phosphatases MAPK phosphatase (MKP)-1 and MKP-3 reciprocally regulate Leishmania major infection.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21471446","citation_count":40,"is_preprint":false},{"pmid":"25499223","id":"PMC_25499223","title":"TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.","date":"2014","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/25499223","citation_count":37,"is_preprint":false},{"pmid":"14701731","id":"PMC_14701731","title":"MKP-3 has essential roles as a negative regulator of the Ras/mitogen-activated protein kinase pathway during Drosophila development.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14701731","citation_count":37,"is_preprint":false},{"pmid":"21300799","id":"PMC_21300799","title":"Dual-specific phosphatase-6 (Dusp6) and ERK mediate AMPA receptor-induced oligodendrocyte death.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21300799","citation_count":36,"is_preprint":false},{"pmid":"22848708","id":"PMC_22848708","title":"Ischemia/reperfusion-induced MKP-3 impairs endothelial NO formation via inactivation of ERK1/2 pathway.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22848708","citation_count":36,"is_preprint":false},{"pmid":"18058922","id":"PMC_18058922","title":"Expression of ERK signaling inhibitors Dusp6, Dusp7, and Dusp9 during mouse ear development.","date":"2008","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/18058922","citation_count":33,"is_preprint":false},{"pmid":"30850165","id":"PMC_30850165","title":"Tripartite motif-containing protein 7 regulates hepatocellular carcinoma cell proliferation via the DUSP6/p38 pathway.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30850165","citation_count":31,"is_preprint":false},{"pmid":"23839489","id":"PMC_23839489","title":"DUSP6 regulates drug sensitivity by modulating DNA damage response.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23839489","citation_count":31,"is_preprint":false},{"pmid":"24946098","id":"PMC_24946098","title":"FOXO1-dependent up-regulation of MAP kinase phosphatase 3 (MKP-3) mediates glucocorticoid-induced hepatic lipid accumulation in mice.","date":"2014","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24946098","citation_count":31,"is_preprint":false},{"pmid":"34686346","id":"PMC_34686346","title":"Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34686346","citation_count":29,"is_preprint":false},{"pmid":"33103082","id":"PMC_33103082","title":"CIC Is a Mediator of the ERK1/2-DUSP6 Negative Feedback Loop.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/33103082","citation_count":28,"is_preprint":false},{"pmid":"30506106","id":"PMC_30506106","title":"DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway.","date":"2019","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/30506106","citation_count":28,"is_preprint":false},{"pmid":"34475393","id":"PMC_34475393","title":"DUSP6 expression is associated with osteoporosis through the regulation of osteoclast differentiation via ERK2/Smad2 signaling.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34475393","citation_count":27,"is_preprint":false},{"pmid":"36806557","id":"PMC_36806557","title":"N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/36806557","citation_count":27,"is_preprint":false},{"pmid":"29493888","id":"PMC_29493888","title":"Dual specificity phosphatase DUSP6 promotes endothelial inflammation through inducible expression of ICAM-1.","date":"2018","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/29493888","citation_count":27,"is_preprint":false},{"pmid":"32231719","id":"PMC_32231719","title":"Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway.","date":"2020","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32231719","citation_count":27,"is_preprint":false},{"pmid":"34689179","id":"PMC_34689179","title":"NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34689179","citation_count":26,"is_preprint":false},{"pmid":"23637337","id":"PMC_23637337","title":"Lef1 regulates Dusp6 to influence neuromast formation and spacing in the zebrafish posterior lateral line primordium.","date":"2013","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23637337","citation_count":26,"is_preprint":false},{"pmid":"31027181","id":"PMC_31027181","title":"Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31027181","citation_count":25,"is_preprint":false},{"pmid":"22155192","id":"PMC_22155192","title":"The genetic association of DUSP6 with bipolar disorder and its effect on ERK activity.","date":"2011","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/22155192","citation_count":25,"is_preprint":false},{"pmid":"32888955","id":"PMC_32888955","title":"MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance.","date":"2020","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/32888955","citation_count":25,"is_preprint":false},{"pmid":"11035444","id":"PMC_11035444","title":"Association study on the DUSP6 gene, an affective disorder candidate gene on 12q23, performed by using fluorescence resonance energy transfer-based melting curve analysis on the LightCycler.","date":"2000","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/11035444","citation_count":25,"is_preprint":false},{"pmid":"22521266","id":"PMC_22521266","title":"MEK/ERK pathway mediates insulin-promoted degradation of MKP-3 protein in liver cells.","date":"2012","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22521266","citation_count":24,"is_preprint":false},{"pmid":"35784390","id":"PMC_35784390","title":"Cynarin attenuates LPS-induced endothelial inflammation via upregulation of the negative regulator MKP-3.","date":"2022","source":"Animal cells and systems","url":"https://pubmed.ncbi.nlm.nih.gov/35784390","citation_count":23,"is_preprint":false},{"pmid":"25414256","id":"PMC_25414256","title":"p53 protein-mediated up-regulation of MAP kinase phosphatase 3 (MKP-3) contributes to the establishment of the cellular senescent phenotype through dephosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2).","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25414256","citation_count":23,"is_preprint":false},{"pmid":"26309510","id":"PMC_26309510","title":"MicroRNA-145 inhibits human papillary cancer TPC1 cell proliferation by targeting DUSP6.","date":"2015","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26309510","citation_count":23,"is_preprint":false},{"pmid":"30577494","id":"PMC_30577494","title":"ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.","date":"2018","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/30577494","citation_count":23,"is_preprint":false},{"pmid":"22848439","id":"PMC_22848439","title":"Mapping MKP-3/FOXO1 interaction and evaluating the effect on gluconeogenesis.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22848439","citation_count":22,"is_preprint":false},{"pmid":"31553703","id":"PMC_31553703","title":"Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.","date":"2019","source":"Radiology and oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31553703","citation_count":22,"is_preprint":false},{"pmid":"33431056","id":"PMC_33431056","title":"Upregulation of DUSP6 impairs infectious bronchitis virus replication by negatively regulating ERK pathway and promoting apoptosis.","date":"2021","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/33431056","citation_count":22,"is_preprint":false},{"pmid":"34792688","id":"PMC_34792688","title":"Short-Chain Fatty Acid Decreases the Expression of CEBPB to Inhibit miR-145-Mediated DUSP6 and Thus Further Suppresses Intestinal Inflammation.","date":"2021","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/34792688","citation_count":22,"is_preprint":false},{"pmid":"31164954","id":"PMC_31164954","title":"Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes.","date":"2019","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/31164954","citation_count":22,"is_preprint":false},{"pmid":"36208663","id":"PMC_36208663","title":"Insights into the role of P2X7R/DUSP6/ERK1/2 and SIRT2/MDM2 signaling in the nephroprotective effect of berberine against cisplatin-induced renal fibrosis in rats.","date":"2022","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36208663","citation_count":21,"is_preprint":false},{"pmid":"24260056","id":"PMC_24260056","title":"DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma.","date":"2013","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24260056","citation_count":21,"is_preprint":false},{"pmid":"29375309","id":"PMC_29375309","title":"P2X7 Nucleotide and EGF Receptors Exert Dual Modulation of the Dual-Specificity Phosphatase 6 (MKP-3) in Granule Neurons and Astrocytes, Contributing to Negative Feedback on ERK Signaling.","date":"2018","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29375309","citation_count":21,"is_preprint":false},{"pmid":"20806045","id":"PMC_20806045","title":"DUSP5 and DUSP6 modulate corneal epithelial cell proliferation.","date":"2010","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/20806045","citation_count":20,"is_preprint":false},{"pmid":"32705203","id":"PMC_32705203","title":"DUSP6 protects murine podocytes from high glucose‑induced inflammation and apoptosis.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32705203","citation_count":20,"is_preprint":false},{"pmid":"31238530","id":"PMC_31238530","title":"Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31238530","citation_count":20,"is_preprint":false},{"pmid":"22171919","id":"PMC_22171919","title":"Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype.","date":"2012","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/22171919","citation_count":20,"is_preprint":false},{"pmid":"30552945","id":"PMC_30552945","title":"The testosterone metabolite 3α-androstanediol inhibits oxidative stress-induced ERK phosphorylation and neurotoxicity in SH-SY5Y cells through an MKP3/DUSP6-dependent mechanism.","date":"2018","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/30552945","citation_count":19,"is_preprint":false},{"pmid":"26379838","id":"PMC_26379838","title":"Silencing of DUSP6 gene by RNAi-mediation inhibits proliferation and growth in MDA-MB-231 breast cancer cells: an in vitro study.","date":"2015","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26379838","citation_count":19,"is_preprint":false},{"pmid":"15541888","id":"PMC_15541888","title":"Effect of hypoxia on the expression and activity of mitogen-activated protein (MAP) kinase-phosphatase-1 (MKP-1) and MKP-3 in neuronal nuclei of newborn piglets: the role of nitric oxide.","date":"2004","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15541888","citation_count":18,"is_preprint":false},{"pmid":"32917360","id":"PMC_32917360","title":"Mice lacking DUSP6/8 have enhanced ERK1/2 activity and resistance to diet-induced obesity.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32917360","citation_count":17,"is_preprint":false},{"pmid":"33146694","id":"PMC_33146694","title":"TRIM65 Promotes Invasion of Endometrial Stromal Cells by Activating ERK1/2/C-myc Signaling via Ubiquitination of DUSP6.","date":"2021","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33146694","citation_count":17,"is_preprint":false},{"pmid":"36478044","id":"PMC_36478044","title":"A DUSP6 inhibitor suppresses inflammatory cardiac remodeling and improves heart function after myocardial infarction.","date":"2022","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/36478044","citation_count":16,"is_preprint":false},{"pmid":"30289454","id":"PMC_30289454","title":"Dusp6 is a genetic modifier of growth through enhanced ERK activity.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30289454","citation_count":16,"is_preprint":false},{"pmid":"24155322","id":"PMC_24155322","title":"Spinal mitogen-activated protein kinase phosphatase-3 (MKP-3) is necessary for the normal resolution of mechanical allodynia in a mouse model of acute postoperative pain.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24155322","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54344,"output_tokens":10046,"usd":0.156861,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20337,"output_tokens":5157,"usd":0.115305,"stage2_stop_reason":"end_turn"},"total_usd":0.272166,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"MKP-3/DUSP6 is catalytically activated by direct binding to ERK2; activation requires ERK2 binding to the noncatalytic N-terminus of MKP-3 and is independent of ERK2 kinase activity. The gain-of-function ERK2 mutant D319N, JNK/SAPK, and p38 did not bind MKP-3 or activate it.\",\n      \"method\": \"In vitro binding and phosphatase activity assays with purified recombinant proteins; mutagenesis (Sevenmaker D319N ERK2)\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified proteins, mutagenesis, replicated across multiple labs\",\n      \"pmids\": [\"9596579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Pyst1/DUSP6 is a cytoplasmic (not nuclear) dual-specificity phosphatase that selectively dephosphorylates and inactivates ERK/MAP kinase but displays very low activity toward JNK/SAPK and p38 in vitro and in vivo; it forms a physical complex with endogenous MAP kinase in cells.\",\n      \"method\": \"Subcellular fractionation/immunofluorescence in transfected Cos-1 cells; in vitro phosphatase assay; co-immunoprecipitation; in vivo kinase assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (fractionation, in vitro assay, co-IP, in vivo inhibition), replicated across labs\",\n      \"pmids\": [\"8670865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MKP-3/DUSP6 is a cytosolic dual-specificity phosphatase that blocks ERK2 phosphorylation and enzymatic activation when expressed in COS-7 cells; subcellular localization in sympathetic neurons is cytosolic with nuclear exclusion.\",\n      \"method\": \"Transfection in COS-7 cells with kinase assays; in situ hybridization; epitope-tag immunolocalization in neurons\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization experiments plus functional kinase assays, replicated across labs\",\n      \"pmids\": [\"8626780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"MKP-3/DUSP6 selectively inactivates ERK1 but only partially inhibits JNK/SAPK and p38 upon co-expression in COS-7 cells, demonstrating reciprocal selectivity compared to M3/6 phosphatase.\",\n      \"method\": \"Co-transfection in COS-7 cells; kinase activity assays; dose-response co-transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple kinase substrates tested, reciprocal selectivity controls, replicated across labs\",\n      \"pmids\": [\"8910287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Crystal structure of the Pyst1/DUSP6 catalytic domain at 2.35 Å reveals a protein tyrosine phosphatase fold with a distorted active site; kinetic analysis shows the catalytic domain is sufficient to dephosphorylate ERK2 and is allosterically activated by inactive ERK2; mutation of Asp262 (5.5 Å from active site) abolishes catalysis in the ERK2-dependent high-activity conformation but not the low-activity form, indicating ERK2 induces closure of the Asp262 loop over the active site.\",\n      \"method\": \"X-ray crystallography (2.35 Å); kinetic assays with pNPP substrate; site-directed mutagenesis (D262A)\",\n      \"journal\": \"Nature structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with mutagenesis and kinetic assays in a single rigorous study\",\n      \"pmids\": [\"10048930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The cytoplasmic localization of MKP-3/DUSP6 is mediated by a CRM1-dependent nuclear export signal (NES) in its N-terminal noncatalytic domain; MKP-3 undergoes active nuclear-cytoplasmic shuttling. The NES and kinase interaction motif (KIM) function independently: KIM mutations abolish ERK2 binding without affecting localization, and NES mutations do not affect ERK2 binding or phosphatase activity. MKP-3 requires both a functional KIM and NES to cause cytoplasmic retention of ERK2.\",\n      \"method\": \"GFP-fusion live-cell imaging; leptomycin B treatment; domain deletion and point mutations; co-immunoprecipitation; FRAP/nuclear translocation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (LMB, mutagenesis, GFP imaging, co-IP), clear mechanistic dissection\",\n      \"pmids\": [\"15269220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ERK2 phosphorylates MKP-3/DUSP6 on serines 159 and 197 in vitro and in vivo, promoting its proteasomal degradation in a MEK1/2-ERK1/2-dependent manner; double S159A/S197A mutants have ~3-fold longer half-life; this phosphorylation does not affect MKP-3 catalytic activity, constituting a positive feedback loop of ERKs on their own activity.\",\n      \"method\": \"In vitro phosphorylation assays with GST-MKP-3 fusion proteins; tetracycline-inducible cell lines; cycloheximide chase; proteasome inhibitor experiments; single and double serine mutant analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with mutagenesis confirmed in multiple cell-based systems, rigorous controls\",\n      \"pmids\": [\"15632084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In mouse embryos, FGFR signaling is required for Dusp6 transcription; targeted inactivation of Dusp6 increases pERK levels and pERK target expression, demonstrating that DUSP6 acts as an in vivo negative feedback regulator of FGFR-ERK signaling during development.\",\n      \"method\": \"Conditional/targeted gene knockout in mice; immunohistochemistry for pERK; qRT-PCR; histological phenotype analysis\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with defined molecular readout (pERK elevation), confirmed by multiple phenotypic endpoints\",\n      \"pmids\": [\"17164422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Pyst1/MKP3 expression in chick embryo neural plate and limb bud is induced downstream of FGF signaling via the MAPK cascade (blocked by FGFR inhibitor SU5402 or MEK inhibitor PD184352); overexpression of Pyst1 reduces activated MAPK levels, alters neural plate morphology, and retards limb bud outgrowth, demonstrating a negative feedback loop on FGF-MAPK signaling in vivo.\",\n      \"method\": \"Tissue transplantation/ablation; FGF protein application; pharmacological inhibitors (SU5402, PD184352); retroviral overexpression in chick embryos\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vivo perturbations (genetic, pharmacological, protein application) converging on same conclusion\",\n      \"pmids\": [\"12814546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FGF-induced DUSP6/MKP-3 transcription is driven by ERK1/2 signaling acting through a conserved Ets-factor binding site in the DUSP6 promoter; Ets2, a known ERK target, binds the endogenous DUSP6 promoter. The DUSP6 promoter-EGFP reporter recapitulates endogenous expression in chick neural plate dependent on FGFR, MAPK, and Ets-binding site integrity.\",\n      \"method\": \"Pharmacological inhibitors; promoter-reporter assays; ChIP; EGFP transgenic embryo experiments; mutagenesis of Ets-binding site\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP on endogenous promoter, mutagenesis, and in vivo reporter assays using multiple methods\",\n      \"pmids\": [\"18321244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Dusp6-null mice show increased basal ERK1/2 phosphorylation in multiple tissues (heart, spleen, kidney, brain, fibroblasts) but no change in ERK5, p38, or JNK activation; loss of Dusp6 increases myocyte proliferation during cardiac development, resulting in cardiac hypercellularity protective against pressure overload and MI. Dusp6-/- MEFs show reduced apoptosis.\",\n      \"method\": \"Gene-targeted knockout mouse; western blotting; histology; cardiomyocyte proliferation assays; pressure-overload and MI models; MEF apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with multiple defined molecular (pERK specificity) and cellular (proliferation, apoptosis) readouts across multiple tissues and disease models\",\n      \"pmids\": [\"18753132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"DUSP6/MKP3 binds ERK1/2 in yeast and human cells but fails to bind ERK5; recombinant ERK2 activates DUSP6 catalytically whereas ERK5 cannot; DUSP6 dephosphorylates co-expressed ERK2 but not ERK5; DUSP6 blocks MEK1-driven ERK1/2 target transcription but not MEK5-driven ERK5 target transcription, confirming strict ERK1/2 specificity.\",\n      \"method\": \"Yeast two-hybrid; co-immunoprecipitation in human cells; in vitro catalytic activation assay; co-expression dephosphorylation assay; transcriptional reporter assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (yeast 2H, co-IP, in vitro assay, reporter) all converging on same conclusion\",\n      \"pmids\": [\"18280112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BCI (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one is a small-molecule allosteric inhibitor of Dusp6 identified by zebrafish chemical screen; docking simulations predicted an allosteric binding site within the phosphatase domain; in vitro studies support a model in which BCI inhibits Dusp6 catalytic activation by blocking ERK2 substrate-induced activation.\",\n      \"method\": \"Transgenic zebrafish chemical screen; molecular docking; in vitro phosphatase activity assays with ERK2\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vivo screen, in vitro mechanistic assays, structural docking, multiple orthogonal validations\",\n      \"pmids\": [\"19578332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The PI3K/mTOR pathway contributes to serum-induced phosphorylation and proteasomal degradation of DUSP6; amino acids and insulin/IGF-1 (mTOR agonists that do not activate ERK) also induce DUSP6 phosphorylation and degradation, requiring basal MEK activity; mutagenesis identified serine 159 as the specific mTOR pathway target on DUSP6.\",\n      \"method\": \"Pharmacological inhibitors (PI3K, mTOR, MEK); tetracycline-inducible cell lines; serine mutagenesis; cycloheximide chase; western blotting\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus pharmacological inhibitors in cell-based system, single lab\",\n      \"pmids\": [\"18223677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DUSP6 mRNA stability is regulated by MEK/ERK signaling via the 3'UTR; hypoxia (HIF-1-dependent) also increases DUSP6 mRNA stability via the 3'UTR, requiring basal ERK activity; Tristetraprolin (TTP) and PUM2 reduce DUSP6 mRNA stability and expression.\",\n      \"method\": \"Luciferase 3'UTR reporter assays; mRNA stability assays with actinomycin D; pharmacological inhibitors; siRNA knockdown\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3'UTR reporter assays plus endogenous mRNA stability measurements, single lab, multiple methods\",\n      \"pmids\": [\"20665674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"DUSP6 dephosphorylates Drp1 at serine 616 independently of its known substrates ERK1/2, keeping Drp1-S616 phosphorylation low under normal conditions and preventing mitochondrial fragmentation and apoptosis. DUSP6 is SUMOylated at lysine 234 by SUMO1/2/3; SUMOylation maintains DUSP6 stability and catalytic function. Under oxidative stress, SENP1 is upregulated, causing deSUMOylation and DUSP6 degradation via ubiquitin-proteasome, leading to Drp1-S616 hyperphosphorylation and mitochondrial fragmentation; overexpression of WT but not the SUMOylation-deficient DUSP6-K234R mutant is protective.\",\n      \"method\": \"Co-immunoprecipitation; SUMOylation assays; phosphatase activity assays; site-directed mutagenesis (K234R); cell-based apoptosis assays; in vivo brain ischemia/reperfusion model\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (Co-IP, mutagenesis, in vitro and in vivo), identifies new substrate and PTM in a single rigorous study\",\n      \"pmids\": [\"32232156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MKP-3/DUSP6 interacts with FOXO1 via residues 200–260 of MKP-3 and residues 360–456 of FOXO1; MKP-3 phosphatase activity (not the interaction itself) is required for FOXO1 nuclear translocation and gluconeogenic gene (G6Pase) transcription; ERK-phosphorylation-deficient FOXO1 loses interaction with MKP-3.\",\n      \"method\": \"Adenoviral overexpression; mutagenesis of MKP-3 and FOXO1; co-immunoprecipitation; glucose output assays; in vivo liver knockdown rescue experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mapping by mutagenesis and co-IP, in vivo rescue, single lab\",\n      \"pmids\": [\"22848439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"DUSP6 depletion in AML cells harboring FLT3-ITD reduces ERK1/2 dephosphorylation and attenuates FLT3-ITD-dependent cell proliferation; high DUSP6 expression in FLT3-ITD cells is causally dependent on FLT3-ITD kinase activity and ERK signaling (shown by pharmacological inhibition and siRNA knockdown).\",\n      \"method\": \"siRNA/shRNA knockdown; pharmacological FLT3 and ERK inhibitors; proliferation assays; western blotting\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — siRNA plus pharmacological inhibitors, multiple cell lines, single lab\",\n      \"pmids\": [\"22784513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PR-B interacts with DUSP6 via a common docking (CD) domain in PR-B N-terminus; DUSP6 acts as a scaffold for CK2-dependent phosphorylation of PR-B at Ser81, which is required for recruitment of a PR-B/DUSP6/CK2 transcriptional complex to the Wnt1 enhancer and expression of STAT5A and Wnt1 target genes in breast cancer cells.\",\n      \"method\": \"Binding studies (Co-IP/pulldown); CD domain mutagenesis; ChIP; luciferase reporter assays; western blotting\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, mutagenesis, and ChIP, single lab\",\n      \"pmids\": [\"23921636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PKN2 phosphorylates and activates DUSP6 through direct association, as confirmed by co-immunoprecipitation and kinase activity assay; activated DUSP6 suppresses ERK1/2 activation, thereby reducing IL-4 and IL-10 expression from colon cancer cells and inhibiting M2 macrophage polarization.\",\n      \"method\": \"Co-immunoprecipitation; kinase activity assay; luciferase assay; ChIP-qPCR; siRNA knockdown; in vitro/in vivo tumor models\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and kinase assay establishing direct interaction and activation, multiple functional readouts, single lab\",\n      \"pmids\": [\"29368606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"DUSP6 transcription in human pancreatic cancer cells is regulated by MAPK1/ERK2 through an ETS transcription factor binding site in intron 1, with ETS2 specifically associating with this region; this constitutes a feedback loop where MAPK1 drives its own negative regulator's expression.\",\n      \"method\": \"Promoter-reporter assays; ChIP; pharmacological inhibitor experiments; mutagenesis of ETS binding site\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP on endogenous locus plus reporter mutagenesis, single lab\",\n      \"pmids\": [\"18848526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"DUSP6 overexpression in corneal epithelial cells prevents ERK1/2 phosphorylation and reduces proliferation rates by >50%; this establishes a functional link between DUSP6-mediated ERK dephosphorylation and control of epithelial cell proliferation.\",\n      \"method\": \"Lentiviral overexpression; immunoblotting; [3H]-thymidine proliferation assays\",\n      \"journal\": \"Molecular vision\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct overexpression with functional proliferation readout, but single lab and single method for DUSP6 OE\",\n      \"pmids\": [\"20806045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The transcriptional repressor CIC directly represses DUSP6 transcription by binding three cis-regulatory elements (CREs) in the DUSP6 promoter. ERK1/2 activates p90RSK, which phosphorylates CIC at S173 and S301, creating a 14-3-3 recognition motif that promotes nuclear export of CIC, thereby derepressing DUSP6 transcription.\",\n      \"method\": \"ChIP; promoter-reporter assays; mutagenesis; co-immunoprecipitation; 14-3-3 binding assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and mutagenesis plus Co-IP, single lab, mechanistically detailed\",\n      \"pmids\": [\"33103082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-181a directly represses DUSP6 protein expression in naive CD4+ T cells; age-associated decline in miR-181a increases DUSP6 protein, which dephosphorylates ERK after TCR stimulation, impairing T cell activation. Reconstitution of miR-181a or siRNA knockdown of DUSP6 restores ERK phosphorylation and T cell responses; allosteric DUSP6 inhibition (BCI) similarly improves TCR-induced ERK signaling.\",\n      \"method\": \"miRNA reconstitution; siRNA knockdown; western blotting; flow cytometry; proliferation and activation marker assays; pharmacological inhibition\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple knockdown approaches with functional readouts, but no direct binding assay for miR-181a/DUSP6\",\n      \"pmids\": [\"23023500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DUSP6 deficiency in T cells leads to enhanced JNK and p38 phosphorylation but impaired glycolysis; DUSP6-/- T cells cannot induce phosphofructokinase activity and rely on fatty acid oxidation; JNK/p38 inhibitors reduce IL-21 production but do not restore glycolysis, indicating DUSP6 connects TCR signaling to metabolic commitment toward glycolysis separately from TFH cytokine regulation.\",\n      \"method\": \"DUSP6-/- mouse model; metabolic assays (glycolysis, phosphofructokinase activity, fatty acid oxidation); phospho-kinase western blotting; pharmacological JNK/p38 inhibitors; in vivo immunization\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO with metabolic and signaling readouts, single lab\",\n      \"pmids\": [\"30087184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DUSP6 directly dephosphorylates SMAD2, and immunoprecipitation confirmed this interaction; DUSP6-mediated ERK2 and SMAD2 dephosphorylation regulates nuclear translocation of NFATC1 and inhibits osteoclast differentiation.\",\n      \"method\": \"Co-immunoprecipitation; western blotting; ERK2-deficient BMM analysis; DUSP6 overexpression and siRNA knockdown; in vitro osteoclastogenesis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and functional assays establish SMAD2 as a DUSP6 substrate, single lab\",\n      \"pmids\": [\"34475393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In neutrophils, DUSP6 is transcriptionally activated by p38-C/EBPβ signaling and acts as an effector maintaining p-p38 activity by downregulating pERK and p38-targeting phosphatases DUSP1/DUSP16; neutrophil-specific Dusp6 knockout attenuates cardiac damage after myocardial infarction.\",\n      \"method\": \"Rat nonsense-mutation strain; bone marrow transplantation; neutrophil-specific conditional KO mice; neutrophil-cardiomyocyte co-culture; western blotting; cardiac functional measurements\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic models (global and cell-specific KO, BMT) with defined pathway readouts, single lab\",\n      \"pmids\": [\"36335128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression; ectopic DUSP6 expression exacerbated disease in PDX models; pharmacological DUSP6 inhibition reduced S6 kinase and JAK-STAT signaling and suppressed inflammatory cytokine production, defining a DUSP6-RSK1 axis.\",\n      \"method\": \"Single-cell RNA-seq; DUSP6 ectopic expression in PDX models; pharmacological DUSP6 inhibition; Jak2V617F and MPLW515L MPN mouse models; western blotting for S6 and JAK-STAT pathway components\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo PDX and mouse models with defined signaling readouts, single lab\",\n      \"pmids\": [\"36581736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FBXO31 is the substrate receptor of CRL1 ubiquitin ligase that promotes ubiquitylation-mediated degradation of DUSP6; depletion of FBXO31 stabilizes DUSP6, suppresses ERK signaling, and paradoxically activates PI3K-AKT signaling; BCI treatment of FBXO31-depleted cells suppresses AKT activation and prevents tumor formation, indicating tumor suppressor activity of FBXO31 is DUSP6-dependent.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitylation assays; shRNA depletion; western blotting; mouse orthotopic tumor model; pharmacological inhibition with BCI\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ubiquitylation assays identify FBXO31 as DUSP6 E3 ligase, in vivo rescue with BCI, single lab\",\n      \"pmids\": [\"34686346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIM65 promotes ubiquitination and degradation of DUSP6, resulting in ERK1/2 activation and C-myc induction in endometrial stromal cells; C-myc in turn promotes TRIM65 expression, creating a feedback loop; ERK1/2 inhibition reverses these effects in vivo.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitylation assay; dual luciferase assay; ChIP; western blotting; in vivo mouse EM model\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and ubiquitylation assays identify TRIM65 as DUSP6 E3 ligase, in vivo validation, single lab\",\n      \"pmids\": [\"33146694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MEF2D functions as a p38MAPK-dependent transcriptional repressor of Dusp6 in skeletal myoblasts; MEF2A binds the Dusp6 genomic locus (identified by ChIP-exo); siRNA targeting MEF2A/D reveals divergent regulation of Dusp6 in cardiac versus skeletal myogenic lineages.\",\n      \"method\": \"ChIP-exo; RNA-seq of MEF2A-depleted cells; siRNA knockdown; promoter-reporter assays; pharmacological p38 inhibition\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-exo plus RNA-seq and siRNA in multiple cell types, single lab\",\n      \"pmids\": [\"25217591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DUSP6 promotes endothelial inflammation by facilitating TNF-α-induced ICAM-1 expression through canonical NF-κB-mediated transcription, independently of ERK signaling; DUSP6 knockout mice show reduced ICAM-1 in aorta/vein and reduced neutrophil recruitment and susceptibility to lung injury in sepsis models.\",\n      \"method\": \"DUSP6 knockout mice; RNAi in HUVECs; ICAM-1 reporter assays; NF-κB pathway analysis; LPS/TNF-α sepsis model\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mice plus RNAi with in vivo and in vitro functional readouts, single lab; ERK-independence determined by pharmacological methods\",\n      \"pmids\": [\"29493888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In oligodendrocytes, DUSP6 overexpression increases AMPA receptor-induced inward currents and cytosolic calcium overload, while blocking DUSP6 expression (enhancing ERK1/2 phosphorylation) significantly reduces AMPA receptor-induced oligodendrocyte death; ERK pathway inhibition (UO126) potentiates excitotoxic death and increases mitochondrial dysfunction, demonstrating that DUSP6-controlled ERK levels regulate AMPA receptor permeability and oligodendroglial excitotoxicity.\",\n      \"method\": \"Microarray and qPCR; DUSP6 knockdown; pharmacological MAPK/ERK inhibition (UO126); patch-clamp electrophysiology; calcium imaging; cell death assays; in vivo optic nerve analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods including electrophysiology and cell death assays, single lab\",\n      \"pmids\": [\"21300799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MKP-3/DUSP6 is required for normal resolution of acute postoperative pain; MKP-3 knockout mice develop persistent mechanical allodynia with sustained spinal pERK and p-p38 (in neurons and microglia); pharmacological inhibition of ERK or p38 reduced persistent allodynia in KO mice, demonstrating DUSP6 normally terminates MAPK activity to resolve pain.\",\n      \"method\": \"MKP-3 KO mice; paw incision pain model; behavioral allodynia assays; western blotting for pERK/p-p38; pharmacological MAPK inhibitors; immunofluorescence\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO with behavioral and molecular readouts, single lab\",\n      \"pmids\": [\"24155322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In DBA/2J mice, a Met62Ile substitution in DUSP6 reduces the interaction between DUSP6 and ERK, resulting in increased ERK phosphorylation and activity; this hypomorphic allele acts as a genetic modifier of body mass in muscular dystrophy through enhanced ERK activity.\",\n      \"method\": \"Whole-genome sequencing; RNA-seq; co-immunoprecipitation to measure ERK binding; pharmacological DUSP6 inhibition in myoblasts; ERK phosphorylation assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — natural variant mapped to DUSP6-ERK interface by Co-IP, functional verification by kinase assays and inhibitor experiments, single lab\",\n      \"pmids\": [\"30289454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Nitric oxide downregulates MKP-3/DUSP6 by destabilizing its mRNA, leading to decreased MKP-3 protein levels and protection of ERK1/2 from TNFα-induced dephosphorylation in endothelial cells; this protects Bcl-2 from proteolysis and prevents cytochrome c release. NO does not affect MKP-3 phosphatase activity directly.\",\n      \"method\": \"Northern blotting; western blotting; NO donor treatment; MKP-3 overexpression; Bcl-2/cytochrome c measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — mRNA stability and protein level experiments with functional apoptosis readouts, NO independence of phosphatase activity tested by overexpression, single lab\",\n      \"pmids\": [\"10846176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FOXO1-dependent upregulation of MKP-3/DUSP6 mediates glucocorticoid-induced hepatic lipid accumulation; dexamethasone increases MKP-3 protein in hepatoma cells and mouse liver via FOXO1 (FOXO1 knockdown or dominant-negative FOXO1 blocks this); MKP-3 deficient mice are protected from glucocorticoid-induced metabolic side effects.\",\n      \"method\": \"FOXO1 siRNA knockdown; dominant-negative FOXO1 overexpression; MKP-3 KO mice; western blotting; metabolic phenotyping\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic perturbations (siRNA, DN overexpression, KO) with consistent metabolic readouts, single lab\",\n      \"pmids\": [\"24946098\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Drosophila MKP-3 (DMKP-3) specifically binds DERK via its N-terminal ERK-binding domain and suppresses Ras/DERK pathway signaling in vivo; DMKP-3 null mutants show embryonic lethality, severe oogenesis defects, extra photoreceptor cells and wing veins phenocopying gain-of-function DERK mutants; genetic interactions confirm DMKP-3 is indispensable for DERK signaling regulation.\",\n      \"method\": \"Drosophila genetics (null mutants, hypomorphs, overexpression transgenes); genetic interaction analysis with Ras/ERK pathway mutants; in vivo epistasis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple alleles (null, hypomorph, OE) with strong genetic epistasis analysis, ortholog of DUSP6 with consistent domain architecture\",\n      \"pmids\": [\"14701731\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DUSP6/MKP-3 is a cytoplasmic, CRM1-dependent dual-specificity phosphatase that is allosterically activated upon direct binding of ERK1/2 to its N-terminal noncatalytic domain (via a kinase interaction motif), causing closure of a Asp262 loop over the active site to enhance catalytic efficiency; activated DUSP6 then dephosphorylates the TEY motif of ERK1/2 (but not ERK5, JNK, or p38) to terminate MAPK signaling; ERK1/2 in turn phosphorylates DUSP6 at Ser159 and Ser197 to promote its proteasomal degradation (positive feedback on ERK activity) and drives DUSP6 transcription via an Ets2/ETS binding site in the DUSP6 promoter (negative feedback); additional regulation is imposed by mTOR-dependent phosphorylation of Ser159, SUMOylation at Lys234 (stabilizing the protein), ubiquitin ligases FBXO31 and TRIM65 (promoting degradation), and miR-181a (repressing translation); beyond ERK1/2, DUSP6 also dephosphorylates Drp1-Ser616 to limit mitochondrial fission, interacts with FOXO1 to promote hepatic gluconeogenesis, and scaffolds CK2-dependent phosphorylation of progesterone receptor-B, demonstrating phosphatase-independent scaffolding functions in addition to its canonical role as a cytoplasmic ERK1/2 feedback attenuator downstream of FGF and other receptor tyrosine kinase signals.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"DUSP6 (MKP-3/Pyst1) is a cytoplasmic dual-specificity phosphatase that serves as the principal negative-feedback attenuator of ERK1/2 MAP kinase signaling downstream of FGF and other receptor tyrosine kinase inputs [#1, #7, #8]. It selectively dephosphorylates and inactivates ERK1/2 while displaying very low activity toward JNK, p38, and ERK5 [#1, #3, #11], and forms a physical complex with MAP kinase in cells [#1]. DUSP6 is catalytically inert until ERK2 binds its N-terminal noncatalytic domain through a kinase interaction motif; this binding allosterically activates the phosphatase independently of ERK kinase activity by inducing closure of the Asp262 loop over the distorted active site, as resolved by crystallography and kinetic analysis [#0, #4]. Cytoplasmic retention of both DUSP6 and its bound ERK2 substrate depends on a CRM1-dependent nuclear export signal in the N-terminal domain that functions independently of the kinase interaction motif [#5]. The enzyme is embedded in interlocking feedback circuits: ERK1/2 drives DUSP6 transcription through Ets-factor binding sites in the promoter and intron 1 (negative feedback) [#9, #20], while ERK-mediated phosphorylation of DUSP6 at Ser159/Ser197 targets it for proteasomal degradation (positive feedback on ERK activity) [#6]. Genetic ablation in mice and Drosophila elevates phospho-ERK and produces developmental and proliferative phenotypes, confirming its in vivo role in restraining the Ras/ERK pathway [#7, #10, #37]. Beyond ERK1/2, DUSP6 dephosphorylates Drp1-Ser616 to limit mitochondrial fission and apoptosis, an activity gated by SUMOylation at Lys234 [#15], and also dephosphorylates SMAD2 [#25]. It additionally performs phosphatase-dependent and scaffolding functions independent of ERK catalysis, including interaction with FOXO1 to drive hepatic gluconeogenic gene expression [#16] and scaffolding of CK2-dependent PR-B phosphorylation at a Wnt1 enhancer [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that DUSP6 is a cytoplasmic dual-specificity phosphatase with selectivity for ERK over JNK/p38, defining its core enzymatic identity and substrate preference.\",\n      \"evidence\": \"Subcellular fractionation, in vitro and in vivo phosphatase assays, and co-IP in transfected COS/Cos-1 cells\",\n      \"pmids\": [\"8670865\", \"8626780\", \"8910287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ERK selectivity at the molecular level not yet resolved\", \"Did not address how catalytic activity is regulated\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Resolved that DUSP6 is catalytically dormant until ERK2 binds its noncatalytic N-terminus, revealing substrate-induced allosteric activation as the activation mechanism.\",\n      \"evidence\": \"In vitro binding and phosphatase assays with purified recombinant proteins and the D319N ERK2 mutant\",\n      \"pmids\": [\"9596579\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of allosteric activation not yet defined\", \"Did not map the binding motif residues\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Provided the structural mechanism of allosteric activation by showing ERK2 binding closes the Asp262 loop over a distorted active site to render the catalytic domain competent.\",\n      \"evidence\": \"2.35 Å crystal structure of the catalytic domain with kinetic assays and D262A mutagenesis\",\n      \"pmids\": [\"10048930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal of the full-length DUSP6-ERK2 complex\", \"Conformational dynamics of the loop closure inferred rather than directly observed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Distinguished the CRM1-dependent nuclear export signal from the kinase interaction motif, explaining how DUSP6 enforces cytoplasmic retention of ERK2.\",\n      \"evidence\": \"GFP live-cell imaging, leptomycin B, domain mutagenesis, and co-IP in cells\",\n      \"pmids\": [\"15269220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Import pathway / shuttling regulators not identified\", \"Physiological signals that modulate shuttling unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated in vivo that FGF-MAPK signaling induces DUSP6 expression and that DUSP6 feeds back to suppress MAPK, establishing the developmental negative-feedback loop.\",\n      \"evidence\": \"Tissue manipulation, FGF protein application, FGFR/MEK inhibitors, and retroviral overexpression in chick embryos\",\n      \"pmids\": [\"12814546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter elements mediating induction not yet mapped\", \"Did not establish degradation-based feedback\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified ERK-mediated Ser159/Ser197 phosphorylation as a degron signal, defining a positive-feedback arm where ERK destabilizes its own phosphatase.\",\n      \"evidence\": \"In vitro kinase assays, inducible cell lines, cycloheximide chase, and serine mutant analysis\",\n      \"pmids\": [\"15632084\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase for ERK-triggered degradation not identified in this study\", \"Quantitative impact on overall ERK dynamics not modeled\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Confirmed via mammalian and Drosophila genetics that DUSP6 is an indispensable in vivo negative regulator of FGFR/Ras-ERK signaling during development.\",\n      \"evidence\": \"Targeted Dusp6 knockout in mice with pERK IHC/qRT-PCR; Drosophila DMKP-3 null and epistasis analysis\",\n      \"pmids\": [\"17164422\", \"14701731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific contributions only partly resolved\", \"Compensation by other DUSPs not fully addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapped the transcriptional feedback to Ets-factor binding sites (promoter and intron 1) bound by Ets2, and showed tissue-wide pERK specificity in knockouts with proliferative/apoptotic consequences.\",\n      \"evidence\": \"ChIP, promoter-reporter mutagenesis, EGFP transgenics, and gene-targeted KO mice with cardiac phenotyping\",\n      \"pmids\": [\"18321244\", \"18848526\", \"18753132\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Combinatorial control with repressors not yet integrated\", \"Mechanism of proliferation/apoptosis effects downstream of pERK incompletely defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extended DUSP6 regulation beyond ERK by implicating mTOR-dependent Ser159 phosphorylation and 3'UTR-mediated mRNA stability control.\",\n      \"evidence\": \"PI3K/mTOR/MEK inhibitors with serine mutagenesis; 3'UTR luciferase and actinomycin D mRNA stability assays with TTP/PUM2 knockdown\",\n      \"pmids\": [\"18223677\", \"20665674\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mTOR-responsive kinase acting on Ser159 not identified\", \"Single-lab findings without independent replication\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Validated DUSP6 as a druggable target by identifying BCI, a small-molecule allosteric inhibitor that blocks ERK2-induced catalytic activation.\",\n      \"evidence\": \"Transgenic zebrafish chemical screen, molecular docking, and in vitro phosphatase assays\",\n      \"pmids\": [\"19578332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact BCI binding site confirmed only by docking\", \"Selectivity across other DUSPs not fully characterized\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Uncovered phosphatase-dependent non-ERK functions and additional upstream regulators, showing DUSP6 interacts with FOXO1 to drive gluconeogenesis and is repressed by miR-181a in T cells.\",\n      \"evidence\": \"Domain-mapping co-IP, adenoviral/in vivo liver rescue (FOXO1); miRNA reconstitution and siRNA with functional T-cell readouts (miR-181a)\",\n      \"pmids\": [\"22848439\", \"23023500\", \"22784513\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct miR-181a/DUSP6 binding assay\", \"FOXO1 interaction findings from a single lab\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed scaffolding (phosphatase-independent) activity in which DUSP6 organizes CK2-dependent phosphorylation of PR-B to activate Wnt1 target transcription.\",\n      \"evidence\": \"Co-IP/pulldown, common-docking domain mutagenesis, ChIP, and luciferase reporters in breast cancer cells\",\n      \"pmids\": [\"23921636\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding without reciprocal validation\", \"Structural basis of the scaffolding complex unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended transcriptional control to repressive inputs (MEF2A/D, p38-dependent) and demonstrated FOXO1-driven DUSP6 upregulation in glucocorticoid-induced hepatic lipid accumulation.\",\n      \"evidence\": \"ChIP-exo, RNA-seq, siRNA/dominant-negative FOXO1, and KO mouse metabolic phenotyping\",\n      \"pmids\": [\"25217591\", \"24946098\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Lineage-specific divergence of MEF2 regulation mechanistically unresolved\", \"Single-lab findings\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a non-ERK substrate (Drp1-Ser616) and a stabilizing PTM, showing SUMOylation at Lys234 maintains DUSP6 stability/activity and that SENP1-driven deSUMOylation under oxidative stress promotes mitochondrial fragmentation.\",\n      \"evidence\": \"Co-IP, SUMOylation and phosphatase assays, K234R mutagenesis, and in vivo brain ischemia/reperfusion model\",\n      \"pmids\": [\"32232156\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Selectivity of DUSP6 between ERK and Drp1 substrates not mechanistically partitioned\", \"SUMO ligase identity not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified two E3 ligases (FBXO31, TRIM65) controlling DUSP6 turnover and additional substrate (SMAD2), expanding the degradation network and substrate repertoire.\",\n      \"evidence\": \"Co-IP, ubiquitylation assays, shRNA depletion, in vivo tumor/endometrial models (FBXO31, TRIM65); co-IP and osteoclastogenesis assays (SMAD2)\",\n      \"pmids\": [\"34686346\", \"33146694\", \"34475393\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relationship between FBXO31- and TRIM65-mediated degradation not reconciled\", \"Single-lab findings per ligase\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Placed DUSP6 in disease-context signaling axes, including JAK2-inhibitor resistance via a DUSP6-RSK1 axis and neutrophil p38-C/EBPβ-driven DUSP6 maintaining p-p38 after myocardial infarction.\",\n      \"evidence\": \"scRNA-seq, PDX and MPN mouse models, pharmacological DUSP6 inhibition; neutrophil-specific conditional KO and co-culture\",\n      \"pmids\": [\"36581736\", \"36335128\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct enzymatic targets in these contexts not all defined\", \"Single-lab findings\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How DUSP6 partitions its catalytic and scaffolding activities among ERK1/2, Drp1, SMAD2, and protein complexes such as PR-B/CK2 within a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model for substrate selection beyond ERK\", \"Spatial/temporal regulation of non-ERK substrate engagement unknown\", \"Structural basis of scaffolding complexes not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 3, 11, 15, 25]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 4, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 7, 8]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [16, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 2, 5]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 7, 8, 11]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 8, 37]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [6, 28, 29]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MAPK1\", \"MAPK3\", \"FOXO1\", \"PKN2\", \"FBXO31\", \"TRIM65\", \"SMAD2\", \"DNM1L\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}